Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

ABSTRACT:

Background

The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.

Methods

Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.

Results

Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeru

SUBMITTER: Anstead M 

PROVIDER: S-EPMC3696392 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature